Nido Biosciences is shuttering in 2026 after its lead drug candidate for a progressive neuromuscular condition failed to meet ...
Dana-Farber CEO outlines 2026 priorities: AI research, rare disease drug development, and plans for a new 300-bed hospital.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback